The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community
Open accessAbstract
Background— Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, induces endothelial dysfunction. Although elevated ADMA has been associated with an increased risk of cardiovascular disease events and death in referral samples, the prognostic significance of ADMA in the community has not been adequately evaluated. Methods and Results— We related plasma ADMA, l -arginine (Arg), and the ratio of Arg to ADMA to the incidence of cardiovascular disease (fatal or nonfatal myocardial infarction, coronary insufficiency, angina pectoris, stroke or transient ischemic attack, intermittent claudication, or heart failure) and death in 3320 Framingham Offspring Study participants (1769 women; mean age, 59 years). Over a follow-up period of 10.9 years, 281 individuals of 2956 free of cardiovascular disease at baseline developed incident cardiovascular disease, and 285 participants died. In multivariable models adjusting for established risk factors and other biomarkers (B-type natriuretic peptide, renin, homocysteine, urine albumin excretion, and C-reactive protein), ADMA and the ratio of Arg to ADMA were significantly associated with all-cause mortality (adjusted-hazard ratio [HR] per 1-SD increment, 1.21; 95% CI, 1.07 to 1.37; and HR per 1-SD increment, 0.80; 95% CI, 0.69 to 0.93, respectively), whereas Arg was not (HR per 1-SD increment, 0.89; 95% CI, 0.77 to 1.02). We noted effect modification by diabetes status; ADMA was associated with death in individuals without diabetes (adjusted HR per 1-SD increment, 1.30; 95% CI, 1.13 to 1.50) but not in individuals with diabetes (adjusted HR per 1-SD increment, 0.85; 95% CI, 0.62 to 1.16). ADMA, Arg, and the ratio of Arg to ADMA were not associated with cardiovascular disease incidence ( P >0.10). Conclusions— In our large community-based sample, ADMA was significantly associated with all-cause mortality, particularly in nondiabetic individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As pointed out above, the ratio of l-arginine to ADMA appears to be a better indicator of cardiovascular risk (28, 103, 104, 606, 1050).”
From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,589
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
AN INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES
Kannel, W. B., Feinleib, M., McNAMARA, P. M., Garrison, R. J., & Castelli, W. P. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112813 · Cited by 1,639
Palmer, R. M. J., Rees, D. D., Ashton, D. S., & Moncada, S. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)81362-7 · Cited by 1,348
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
Wang, T. J., Gona, P. N., Larson, M. G., Tofler, G. H., Levy, D. A., Newton‐Cheh, C., Jacques, P. F., Rifai, N., Selhub, J., Robins, S. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055373 · Cited by 1,337
Self-citationBöger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Zoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07217-8 · Cited by 1,087
Achan, V., Broadhead, M., Malaki, M., Whitley, G. S. J., LEIPER, J. M., MacAllister, R. J., & Vallance, P. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000081742.92006.59 · Cited by 593
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine
Valkonen, V.-P., Päivä, H., Salonen, J. T., Lakka, T. A., Lehtimäki, T., Laakso, J., & Laaksonen, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07184-7 · Cited by 562
LDL Cholesterol Upregulates Synthesis of Asymmetrical Dimethylarginine in Human Endothelial Cells
Böger, R. H., Sydow, K., Borlak, J. T., Thum, T., Lenzen, H., Schubert, B., Tsikas, D., & Bode‐Böger, S. M. (2000) · Circulation Research · doi:10.1161/01.res.87.2.99 · Cited by 478
Pritchard, K. A., Groszek, L., Smalley, D. M., Sessa, W. C., Wu, M., Villalon, P., Wolin, M. S., & Stemerman, M. B. (1995) · Circulation Research · doi:10.1161/01.res.77.3.510 · Cited by 470
Oxidative stress and diabetic cardiovascular complications
Jay, D., Hitomi, H., & Griendling, K. K. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.06.018 · Cited by 464
Disruption of methylarginine metabolism impairs vascular homeostasis
LEIPER, J. M., Nandi, M., Torondel, B., Murray‐Rust, J., Malaki, M., O'Hara, B. P., Rossiter, S., Anthony, S., Madhani, M., Selwood, D. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1543 · Cited by 408
Kielstein, J. T., Impraim, B., Simmel, S., Bode‐Böger, S. M., Tsikas, D., Frölich, J. C., Hoeper, M. M., Haller, H. G., & Fliser, D. (2003) · Circulation · doi:10.1161/01.cir.0000105764.22626.b1 · Cited by 400
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
Böger, R. H. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00500-5 · Cited by 393
Schnabel, R. B., Blankenberg, S., Lubos, E., Lackner, K. J., Rupprecht, H. J., Espinola–Klein, C., Jachmann, N., Post, F., Peetz, D., Bickel, C., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000181286.44222.61 · Cited by 377
Nitric Oxide and Atherosclerosis
Claudio Napoli, A., & Ignarro, L. J. (2001) · Nitric Oxide · doi:10.1006/niox.2001.0337 · Cited by 374
Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis
Dayoub, H., Achan, V., Adimoolam, S., Jacobi, J., Stuehlinger, M. C., Wang, B., Tsao, P. S., Kimoto, M., Vallance, P. J., Patterson, A. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000101924.04515.2e · Cited by 340
Cardounel, A. J., Cui, H., Samouilov, A., Johnson, W., Kearns, P. N., Tsai, A.-L., Berka, V., & Zweier, J. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603606200 · Cited by 249
Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond
Böger, R. H. (2006) · Annals of Medicine · doi:10.1080/07853890500472151 · Cited by 238
Meinitzer, A., Seelhorst, U., Wellnitz, B., Halwachs‐Baumann, G., Boehm, B. O., Winkelmann, B. R., & März, W. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.076711 · Cited by 227
Lu, T. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.08.013 · Cited by 192
Schwedhelm, E., Maas, R., Tan-Andresen, J., Schulze, F., Riederer, U., & Böger, R. H. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.11.052 · Cited by 168
Self-citationFörstermann, U. (2006) · Biological Chemistry · doi:10.1515/bc.2006.190 · Cited by 155
Mittermayer, F., Krzyżanowska, K., Exner, M., Mlekusch, W., Amighi, J., Sabeti, S., Minar, E., Müller, M. M., Wolzt, M., & Schillinger, M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000242801.38419.48 · Cited by 143
Leong, T., Zylberstein, D. E., Graham, I. M., Lissner, L., Ward, D., Fogarty, J., Bengtsson, C., Björkelund, C., & Thelle, D. S. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.156596 · Cited by 141
Spontaneous Myocardial Infarction in Mice Lacking All Nitric Oxide Synthase Isoforms
Nakata, S., Tsutsui, M., Shimokawa, H., Suda, O., Morishita, T., Shibata, K., Yatera, Y., Sabanai, K., Tanimoto, A., Nagasaki, M., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742692 · Cited by 133
Schwedhelm, E., Tan-Andresen, J., Maas, R., Riederer, U., Schulze, F., & Böger, R. H. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046037 · Cited by 122
Self-citationO’Dwyer, M. J., Dempsey, F., Crowley, V., Kelleher, D. P., McManus, R., & Ryan, T. (2006) · Critical Care · doi:10.1186/cc5053 · Cited by 113
Nicholls, S. J., Wang, Z., Koeth, R., Levison, B. S., DelFraino, B., Džavík, V., Griffith, O. W., Hathaway, D. R., Panza, J. A., Nissen, S. E., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.693986 · Cited by 107
Krempl, T., Maas, R., Sydow, K., Meinertz, T., Böger, R. H., & Kahler, J. P. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi287 · Cited by 94
Self-citationMaas, R., Schulze, F., Baumert, J., Löwel, H., Hamraz, K., Schwedhelm, E., Köenig, W., & Böger, R. H. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081893 · Cited by 85
Self-citationPäivä, H., Lehtimäki, T. J., Laakso, J. T., Ruokonen, I., Rantalaiho, V. M., Wirta, O., Pasternack, A. I., & Laaksonen, R. (2003) · Metabolism · doi:10.1053/meta.2003.50048 · Cited by 83
Quantification of ADMA: analytical approaches
Schwedhelm, E. (2005) · Vascular Medicine · doi:10.1177/1358836x0501000113 · Cited by 83
Self-citationDixon, L., HUGHES, S., ROONEY, K., MADDEN, A., Devine, A. B., Leahey, W. J., HENRY, W., Johnston, G. D., & McVeigh, G. E. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.01.004 · Cited by 70
Krzyżanowska, K., Mittermayer, F., Shnawa, N., Hofer, M., Schnabler, J., Etmüller, Y., Kapiotis, S., Wolzt, M., & Schernthaner, G. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02018.x · Cited by 63
ADMA is independently related to flow‐mediated vasodilation in subjects at low cardiovascular risk
Ardigò, D., Stuehlinger, M., Franzini, L., Valtueña, S., Piatti, P., Pachinger, O. M., Reaven, G. M., & Zavaroni, I. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01781.x · Cited by 46
Maas, R., Dentz, L., Schwedhelm, E., Thoms, W., Kuß, O., Hiltmeyer, N., Haddad, M., KLÖSS, T., Standl, T. G., & Böger, R. H. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000277038.11630.71 · Cited by 41
Self-citation
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Nitric oxide synthases: regulation and function
Forstermann, U., & Sessa, W. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr304 · Cited by 4,409
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses
Fernández-Macías, J. C., Ochoa-Martínez, A. C., Varela-Silva, J. A., & Pérez-Maldonado, I. N. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.08.009 · Cited by 458
Rochette, L., Lorin, J., Zeller, M., Guilland, J.-C., Lorgis, L., Cottin, Y., & Vergely, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.004 · Cited by 456
Endothelial dysfunction : the early predictor of atherosclerosis
Mudau, M., Genis, A., Lochner, A., & Strijdom, H. (2012) · Cardiovascular Journal of Africa · doi:10.5830/cvja-2011-068 · Cited by 521
Metadata
- Authors
- Böger, R. H., Sullivan, L. M., Schwedhelm, E., Wang, T. J., Maas, R., Benjamin, E. J., Schulze, F., Xanthakis, V., Benndorf, R. A., & Vasan, R. S.
- Affiliations
- From the Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (R.H.B., E.S., R.M., F.S., R.A.B.); Framingham Heart Study, Framingham, Mass (L.M.S., T.J.W., E.J.B., V.X., R.S.V.); Department of Biostatistics (L.M.S., V.X.) and Cardiology Division and Preventive Medicine (E.J.B., R.S.V.), Boston University School of Public Health, Boston, Mass; and Cardiology Division, Massachusetts General Hospital, Boston (T.J...
- Boston University (US)
- ORCID
- Venue
- Circulation
- Published
- 2009-03-31
- Volume
- 119
- Issue
- 12
- Pages
- 1592-1600
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC2742491
- OpenAlex
- W2136960413
- Cited by
- 351
- References
- 41
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 11 · 2023: 13 · 2022: 17 · 2021: 10 · 2020: 20 · 2019: 15 · 2018: 21 · 2017: 21 · 2016: 24 · 2015: 33 · 2014: 29 · 2013: 21 · 2012: 29
- FWCI
- 23.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5k23hl074077-03, n01hc25195-41-0-1, n01hv28178-12-0-0)
- National Heart, Lung, and Blood Institute (K23 HL074077-01, 2K24 HL 04334, N01‐HC25195, K23-HL-074077, K24HL004334, N01-HC-025195, N01-HV-028178)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- asymmetric dimethylarginine, L-arginine, endothelial dysfunction, nitric oxide synthase inhibition, cardiovascular disease incidence, all-cause mortality, cardiovascular mortality, diabetes mellitus, Framingham Offspring Study, community-based cohort, prognostic factors
- MeSH terms
- Aged, Arginine, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Follow-Up Studies, Humans, Middle Aged, Mortality, Predictive Value of Tests, Prognosis, Incidence, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
